Clinical trials: Skin Diseases, Bacterial
Urinary Tract Infections, Bacterial Pneumonia
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.
- Conditions
- Urinary Tract Infections, Bacterial Pneumonia, Soft Tissue Infections
- Trial name
- NCT00451386
- Testing
- MK0826, ertapenem sodium /Duration of Treatment: 14 Days, Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis, HIV Infections
Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis
The purpose of this study is to identify differences in TB specific immune responses among immunosuppressed patients latently infected with TB and patients with active TB.
- Conditions
- Tuberculosis, HIV Infections, Rheumatoid Arthritis
- Trial name
- NCT00285441
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Hvidovre University Hospital
Hidradenitis Suppurativa
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. Although adalimumab is recently licensed for moderate to severe HS, many cases fail to respond or relapse during treatment.
- Trial name
- NCT02643654
- Testing
- MABp1
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Evangelos J. Giamarellos-Bourboulis, M.D.
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa
Etanercept in Hidradenitis Suppurativa
The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the…
- Trial name
- NCT00329823
- Testing
- Etanercept sc 50mg per week for 12 weeks
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- University of Athens
Hidradenitis Suppurativa
Spironolactone for Hidradenitis Suppurativa
The purpose of this study is to evaluate if the drug spironolactone - which is used to treat acne and male pattern hair growth in women - is effective in treating hidradenitis suppurativa in females and which dose of the drug…
- Trial name
- NCT04100083
- Testing
- Spironolactone 50 MG, Spironolactone 100mg, Spironolactone 200 mg
- Sponsor
- Medical University of South Carolina
Hidradenitis Suppurativa, Acne Inversa
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period.
- Trial name
- NCT04476043
- Testing
- INCB054707
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 209 people
- Sponsor
- Incyte Corporation
Pneumonia, Bacterial, Pneumonia Childhood
Discharge Stewardship in Children's Hospitals
The goal of this interventional study is to test if a discharge stewardship bundle is effective at reducing inappropriate antibiotic prescriptions at hospital discharge for children with the three common infections…
- Conditions
- Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections
- Trial name
- DISCO (NCT05826873)
- Testing
- Discharge antibiotic stewardship intervention
- Where
- 5 sites in United States
- Volunteers
- 1,131 people
- Sponsor
- Children's Hospital of Philadelphia
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation
Skin Infection, Bacterial Infection
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.
- Trial name
- NCT02052388
- Testing
- Daptomycin, Brilacidin
- Where
- 4 sites in United States
- Volunteers
- 215 people
- Sponsor
- Cellceutix Corporation